SERPINA1 and alpha 1-antitrypsin deficiency: In December 2017, for example, the FDA granted orphan drug status to Organova for their treatment of alpha-1 antitrypsin (A1AT) deficiency based on tests carried out using their 3D bioprinted liver tissues.